INDERAL Drug Patent Profile

When do Inderal patents expire, and when can generic versions of Inderal launch?

Inderal is a drug marketed by Wyeth Ayerst, Wyeth Pharms, and Ani Pharms. and is included in three NDAs.

The generic ingredient in INDERAL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Inderal

A generic version of INDERAL was approved as propranolol hydrochloride by INNOGENIX on October 22^nd, 1985.

Summary for INDERAL

US Patents:	0
Applicants:	3
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	157
Clinical Trials:	76
Patent Applications:	4,079
Drug Prices:	Drug price information for INDERAL
What excipients (inactive ingredients) are in INDERAL?	INDERAL excipients list
DailyMed Link:	INDERAL at DailyMed

See drug prices for INDERAL

Recent Clinical Trials for INDERAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zealand University Hospital	Phase 2
Rigshospitalet, Denmark	Phase 2
Second Xiangya Hospital of Central South University	Phase 1

See all INDERAL clinical trials

US Patents and Regulatory Information for INDERAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	INDERAL	propranolol hydrochloride	SUSPENSION;ORAL	019536-001	Dec 12, 1986		DISCN	No	No
Wyeth Pharms	INDERAL	propranolol hydrochloride	TABLET;ORAL	016418-010	Oct 18, 1982		DISCN	Yes	No
Wyeth Pharms	INDERAL	propranolol hydrochloride	TABLET;ORAL	016418-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ani Pharms	INDERAL LA	propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	018553-004	Mar 18, 1987	AB	RX	Yes	No

Expired US Patents for INDERAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Ayerst	INDERAL	propranolol hydrochloride	SUSPENSION;ORAL	019536-001	Dec 12, 1986	4,600,708

International Patents for INDERAL

See the table below for patents covering INDERAL around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1269619	FORMULATIONS LIQUIDES DE CHLORHYDRATE DE PROPANOLOL (PROPRANOLOL HYDROCHLORIDE LIQUID FORMULATIONS)

INDERAL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Drug: Inderal (Propranolol)

Introduction

Inderal, known generically as propranolol, is a widely used beta-blocker medication primarily prescribed for the treatment of hypertension, angina, heart rhythm disorders, and other cardiovascular conditions. This article delves into the market dynamics and financial trajectory of Inderal, providing insights into its current market size, growth prospects, key drivers, and financial performance.

Market Size and Growth Prospects

The global propranolol market, which includes Inderal, is projected to experience steady growth over the coming years. As of 2023, the market size was valued at USD 0.40 billion and is expected to reach USD 0.53 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 3.2% during this period[1].

Key Drivers of the Market

Several factors are driving the growth of the propranolol market:

Increasing Prevalence of Cardiovascular Diseases

The rising incidence of cardiovascular diseases worldwide is a significant driver. Cardiovascular diseases are among the leading causes of death globally, and the demand for effective treatments like propranolol is increasing accordingly[1].

Growing Awareness of Mental Health Disorders

Propranolol is also used to treat certain mental health conditions, such as performance anxiety and post-traumatic stress disorder (PTSD). The growing awareness and recognition of mental health disorders are contributing to the market's growth[1].

Market Segmentation

The propranolol market is segmented based on several criteria:

Type

The market is primarily segmented into oral and intravenous forms. The oral segment dominates the market due to its ease of consumption, chemical and biological stability, and cost efficiency[3].

Application

Propranolol is used in various applications, including hypertension, angina, heart rhythm management, and other cardiovascular conditions. The arrhythmia segment is expected to expand significantly during the forecast period[4].

Distribution Channels

The market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. Online pharmacies are expected to grow at a higher CAGR due to increasing consumer preference for online shopping and the convenience it offers[3].

End-User

The end-users include hospitals, clinics, home care settings, and ambulatory surgical centers. The demand from these sectors is driven by the need for effective and reliable treatments for cardiovascular and other related conditions[3].

Financial Performance of Key Players

Companies like AstraZeneca, Apotex, Teva, Atnahs Pharma, and Mylan are major players in the propranolol market.

AstraZeneca's Divestment

In 2020, AstraZeneca divested the rights to several established hypertension medicines, including Inderal, to Atnahs Pharma. This deal included an upfront payment of $350 million and potential future sales-contingent payments of up to $40 million between 2020 and 2022[5].

Revenue and Profit Margins

Pharmaceutical companies, including those producing propranolol, generally exhibit high profit margins. A study comparing the profitability of large pharmaceutical companies with S&P 500 companies found that pharmaceutical companies have significantly higher gross profit margins (76.5% vs 37.4%), EBITDA margins (29.4% vs 19%), and net income margins (13.8% vs 7.7%)[2].

Regional Analysis

The propranolol market is geographically segmented into regions such as North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Asia Pacific

The Asia Pacific region is expected to grow with the highest CAGR during the forecast period due to its large and aging population. Countries like Japan, with a rapidly aging society, contribute significantly to this growth[3].

Market Restraints

Despite the growth prospects, there are several restraints that could impact the market:

Competition from Generic Drugs

The availability of generic versions of propranolol can reduce the market share of branded drugs like Inderal.

Regulatory Challenges

Stringent regulatory requirements and the need for continuous compliance can pose challenges for manufacturers.

Economic Factors

Economic downturns and changes in healthcare policies can affect the demand and pricing of pharmaceuticals[4].

Technological and Market Trends

Several trends are shaping the propranolol market:

Online Pharmacies

The rise of online pharmacies is expected to significantly impact the distribution channels, offering greater convenience and accessibility to patients[3].

Increasing Focus on Digital Health

The integration of digital health technologies, such as telemedicine and patient monitoring systems, is likely to influence how propranolol and other medications are prescribed and managed.

Growing Importance of Generic Drugs

Generic drugs are becoming increasingly important due to their cost-effectiveness and the expiration of patents for many branded drugs.

Key Players' Strategies

Major players in the propranolol market are adopting various strategies to strengthen their market position:

Product Portfolio Expansion

Companies like Apotex and Atnahs Pharma are focusing on expanding their product portfolios to include a wider range of formulations and applications[4].

Mergers and Acquisitions

Strategic mergers and acquisitions are common in the pharmaceutical industry, allowing companies to gain access to new markets, technologies, and products.

Research and Development

Continuous investment in research and development is crucial for staying competitive in the market. Companies are focusing on developing new formulations and improving existing ones to meet evolving patient needs.

Conclusion

The propranolol market, including the drug Inderal, is poised for steady growth driven by increasing demand for cardiovascular treatments and growing awareness of mental health disorders. Key players are adopting various strategies to maintain their market position, and the market is influenced by trends such as the rise of online pharmacies and the increasing importance of generic drugs.

Key Takeaways

• The global propranolol market is expected to reach USD 0.53 billion by 2032, growing at a CAGR of 3.2%.
• The oral segment dominates the market due to its ease of consumption and cost efficiency.
• Asia Pacific is expected to grow with the highest CAGR due to its large and aging population.
• Pharmaceutical companies exhibit high profit margins compared to other industries.
• Online pharmacies and digital health technologies are significant trends shaping the market.

FAQs

What is the expected market size of the propranolol market by 2032?

The propranolol market is expected to reach USD 0.53 billion by 2032[1].

What is the CAGR of the propranolol market from 2024 to 2032?

The propranolol market is expected to exhibit a CAGR of 3.2% from 2024 to 2032[1].

Which segment dominates the propranolol market in terms of type?

The oral segment dominates the propranolol market due to its ease of consumption and cost efficiency[3].

What are the key drivers of the propranolol market?

The key drivers include the increasing prevalence of cardiovascular diseases and the growing awareness of mental health disorders[1].

Which region is expected to grow with the highest CAGR in the propranolol market?

The Asia Pacific region is expected to grow with the highest CAGR due to its large and aging population[3].

Sources

1. Business Research Insights: Propranolol Market Size, Share and Forecast, 2024-2032.
2. JAMA Network: Profitability of Large Pharmaceutical Companies Compared With Other S&P 500 Companies.
3. UnivDatos: Propranolol Drug Market: Current Analysis and Forecast (2022-2030).
4. Cognitive Market Research: Propranolol Drug Market Report 2024 (Global Edition).
5. AstraZeneca: AstraZeneca divests rights to established hypertension medicines.